COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,554 Articles (22,400 medRxiv, 8,154 bioRxiv)

Most recent first Previous |  Page 678: Articles 6771-6780  | Next

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Naggie, S.
10.1101/2022.06.10.22276252 — Posted: 2022-06-12
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
Ullah, I., Beaudoin-Bussieres, G., Symmes, K., Cloutier, M., Ducas, E., Tauzin, A., Laumaea, A., Begin, P., Mothes, W., Bazin, R., Finzi, A., Uchil, P. D.
10.1101/2022.06.10.495677 — Posted: 2022-06-12
Hybrid immunity shifts the Fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity
Bowman, K. A., Stein, D., Shin, S., Ferbas, K. G., Tobin, N., Mann, C., Fischinger, S., Ollmann Saphire, E., Lauffenberger, D., Rimoin, A., Aldrovandi, G., Alter, G.
10.1101/2022.06.10.495727 — Posted: 2022-06-11
PandoraRL: DQN and Graph Convolution based ligand pose learning for SARS-COV1 Mprotease
Jose, J., Alam, U., Arora, P., Singh, D., Jatana, N.
10.1101/2022.06.09.495578 — Posted: 2022-06-11
Evolutionary trajectory of the physicochemical mechanism of interaction of SARS-CoV-2 spike protein with ACE2
Planchais, C., Reyes-Ruiz, A., Lacombe, R., Zarantonello, A., Lecerf, M., Revel, M., Roumenina, L. T., Atanasov, B. P., Mouquet, H., Dimitrov, J. D.
10.1101/2022.06.11.495733 — Posted: 2022-06-11
SARS-CoV-2 minor variant genomes at the start of the pandemic contained markers of VoCs
Dong, X., Hiscox, J. A.
10.1101/2022.06.10.495670 — Posted: 2022-06-10
A cellular assay for spike/ACE2 fusion: quantification of fusion-inhibitory antibodies after COVID-19 and vaccination
Abdul, F., Ribaux, P., Caillon, A., Malezieux, A., Prendki, V., Zhukovsky, N., Delhaes, F., Krause, K.-H., Preynat-Seauve, O.
10.1101/2022.06.09.495433 — Posted: 2022-06-09
Tracking infectious entry routes of SARS-CoV-2
Kreutzberger, A. J. B., Sanyal, A., Saminathan, A., Bloyet, L.-M., Stumpf, S., Liu, Z., Ojha, R., Patjas, M. T., Geneid, A., Scanavachi, G., Doyle, C. A., Somerville, E., Cunha Correira, R., Di Caprio, G., Toppila-Salmi, S., Makitie, A., Kiessling, V., Vapalahti, O., Whelan, S. P. J., Balistreri, G., Kirchhausen, T.
10.1101/2022.06.09.495472 — Posted: 2022-06-09
Binding and unbinding pathways of peptide substrate on SARS-CoV-2 3CL protease
Moritsugu, K., Ekimoto, T., Ikeguchi, M., Kidera, A.
10.1101/2022.06.08.495396 — Posted: 2022-06-09
SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response.
Takamatsu, Y., Omata, K., Shimizu, Y., Kinoshita-Iwamoto, N., Terada, M., Suzuki, T., Morioka, S., Uemura, Y., Ohmagari, N., Maeda, K., Mitsuya, H.
10.1101/2022.06.09.495422 — Posted: 2022-06-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).